Do you routinely offer ovarian suppression in addition to aromatase-inhibitor in premenopausal patients under 50 with an intermediate oncotype score (11-25)?
In the setting of the recent TailorRx data, would these patients be considered more high risk?
Would you offer OFS for patients who underwent che...
Dr. @Logan Corey, we have a few related threads, b...